July 20, 2022 / 06:51 PM IST
Reported Standalone quarterly numbers for Gland Pharma are:Net Sales at Rs 856.90 crore in June 2022 down 25.74% from Rs. 1,153.90 crore in June 2021.
Story continues below Advertisement
Quarterly Net Profit at Rs. 229.45 crore in June 2022 down 34.57% from Rs. 350.68 crore in June 2021.
EBITDA stands at Rs. 344.59 crore in June 2022 down 30.82% from Rs. 498.14 crore in June 2021.
Gland EPS has decreased to Rs. 13.95 in June 2022 from Rs. 21.41 in June 2021.
Gland shares closed at 2,449.60 on July 19, 2022 (NSE)
| Gland Pharma | | Standalone Quarterly Results | in Rs. Cr. |
|
| Jun'22 | Mar'22 | Jun'21 | | Net Sales/Income from operations | 856.90 | 1,103.01 | 1,153.90 | | Other Operating Income | -- | -- | -- | | Total Income From Operations | 856.90 | 1,103.01 | 1,153.90 | | EXPENDITURE | | Consumption of Raw Materials | 340.81 | 602.95 | 422.59 | | Purchase of Traded Goods | 4.75 | 8.81 | 4.00 | | Increase/Decrease in Stocks | 28.50 | -66.47 | 109.91 | | Power & Fuel | -- | 25.13 | 22.23 | | Employees Cost | 98.00 | 94.25 | 80.57 | | Depreciation | 34.91 | 31.08 | 25.28 | | Excise Duty | -- | -- | -- | | Admin. And Selling Expenses | -- | -- | -- | | R & D Expenses | -- | -- | -- | | Provisions And Contingencies | -- | -- | -- | | Exp. Capitalised | -- | -- | -- | | Other Expenses | 114.64 | 89.92 | 78.30 | | P/L Before Other Inc. , Int., Excpt. Items & Tax | 235.29 | 317.36 | 411.02 | | Other Income | 74.39 | 65.23 | 61.84 | | P/L Before Int., Excpt. Items & Tax | 309.68 | 382.59 | 472.86 | | Interest | 0.90 | 2.03 | 1.00 | | P/L Before Exceptional Items & Tax | 308.78 | 380.56 | 471.86 | | Exceptional Items | -- | -- | -- | | P/L Before Tax | 308.78 | 380.56 | 471.86 | | Tax | 79.33 | 94.58 | 121.19 | | P/L After Tax from Ordinary Activities | 229.45 | 285.98 | 350.68 | | Prior Year Adjustments | -- | -- | -- | | Extra Ordinary Items | -- | -- | -- | | Net Profit/(Loss) For the Period | 229.45 | 285.98 | 350.68 | | Equity Share Capital | 16.47 | 16.43 | 16.39 | | Reserves Excluding Revaluation Reserves | -- | -- | -- | | Equity Dividend Rate (%) | -- | -- | -- | | EPS Before Extra Ordinary | | Basic EPS | 13.95 | 17.41 | 21.41 | | Diluted EPS | 13.94 | 17.36 | 21.37 | | EPS After Extra Ordinary | | Basic EPS | 13.95 | 17.41 | 21.41 | | Diluted EPS | 13.94 | 17.36 | 21.37 | | Public Share Holding | | No Of Shares (Crores) | -- | -- | -- | | Share Holding (%) | -- | -- | -- | | Promoters and Promoter Group Shareholding | | a) Pledged/Encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | b) Non-encumbered | | - Number of shares (Crores) | -- | -- | -- | | - Per. of shares (as a % of the total sh. of prom. and promoter group) | -- | -- | -- | | - Per. of shares (as a % of the total Share Cap. of the company) | -- | -- | -- | | Source : Dion Global Solutions Limited |
|
Discover the latest business news, Sensex, and Nifty updates. Obtain Personal Finance insights, tax queries, and expert opinions on Moneycontrol or download the Moneycontrol App to stay updated!
